drugset / Trial / NCT01065467
Panobinostat (LBH589) in Patients With Metastatic Melanoma
Phase 1
Completed
16 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the safety of LBH589 as well as to find out what side effects it may cause and how effective it is against melanoma. LBH589 is a drug which may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes, which are proteins normally produced by cells. These enzymes are known to play an important role in the development and reproduction of cancer cells. It is believed that LBH589 works by helping to promote the activity of enzymes which turn on the mechanisms in our cells that suppress cells from becoming cancerous.
Timeline
- Start
- 2010-02
- Primary completion
- 2013-03
- Completion
- 2017-03-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | — | Oral |